Bone marrow microenvironment signatures associate with patient survival after guadecitabine and atezolizumab therapy in HMA-resistant MDS
H. Josh Jang, Guillermo Urrutia, Andreas Due Ørskov, Anh Van Nguyen, Hyeon Jin Kim, Seth A. Nelson, Hyein Lee, Ryan S. Burgos, Benjamin K. Johnson, Marc Wegener, Katelyn Becker, Marie Adams, Rachael T. C. Sheridan, Zachary H. Ramjan, Scott A. Givan, , Peter A. Jones
The paper analyzes bone marrow microenvironment changes in HMA-resistant MDS patients treated with guadecitabine and atezolizumab, finding that long-term survivors show reduced immunosuppressive monocytes and expanded effector lymphocytes.
Blood Neoplasia · May 5, 2026Peer-reviewedCancer Biology